INT79298

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 1998
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 9
Total Number 23
Disease Relevance 4.90
Pain Relevance 3.42

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (NXT1) intracellular (NXT1) cytoplasm (NXT1)
Anatomy Link Frequency
plasma 1
molar 1
urine 1
NXT1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Opioid 47 100.00 Very High Very High Very High
alcohol 28 100.00 Very High Very High Very High
antagonist 28 100.00 Very High Very High Very High
Pain score 2 97.92 Very High Very High Very High
visual analogue scale 6 97.68 Very High Very High Very High
Inflammatory response 5 97.24 Very High Very High Very High
Osteoarthritis 57 95.36 Very High Very High Very High
drug abuse 14 94.72 High High
addiction 33 94.44 High High
opioid receptor 14 93.24 High High
Disease Link Frequency Relevance Heat
Hypercalcemia 19 99.40 Very High Very High Very High
Pain 8 97.80 Very High Very High Very High
INFLAMMATION 5 96.88 Very High Very High Very High
Knee Osteoarthritis 48 95.36 Very High Very High Very High
Drug Dependence 14 94.72 High High
Opiate Addiction 33 94.44 High High
Bone Cancer 6 86.64 High High
Osteoporosis 8 85.52 High High
Disease 6 81.20 Quite High
Malignant Neoplastic Disease 4 80.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The cumulative amount of NTX released at the end of 60 days was 80%.
Localization (released) of NTX
1) Confidence 0.60 Published 2006 Journal Drug Dev Ind Pharm Section Abstract Doc Link 16455607 Disease Relevance 0.07 Pain Relevance 0.12
Compressed microspheres showed near zero-order sustained release of NTX for 360 days.
Localization (release) of NTX
2) Confidence 0.52 Published 2006 Journal Drug Dev Ind Pharm Section Abstract Doc Link 16455607 Disease Relevance 0.08 Pain Relevance 0.13
The sustained release performance of NTX from the biodegradable depot systems may provide a reliable, convenient, and safe mechanism for the administration of NTX for the long-term treatment of opioid dependence.
Localization (release) of NTX associated with addiction and opioid
3) Confidence 0.52 Published 2006 Journal Drug Dev Ind Pharm Section Abstract Doc Link 16455607 Disease Relevance 0.19 Pain Relevance 0.19
The in vitro release profiles of NTX from PLA microspheres showed the release of NTX did not follow zero-order kinetics.
Localization (release) of NTX
4) Confidence 0.52 Published 2006 Journal Drug Dev Ind Pharm Section Abstract Doc Link 16455607 Disease Relevance 0.06 Pain Relevance 0.03
The in vitro release profiles of NTX from PLA microspheres showed the release of NTX did not follow zero-order kinetics.
Localization (release) of NTX
5) Confidence 0.52 Published 2006 Journal Drug Dev Ind Pharm Section Abstract Doc Link 16455607 Disease Relevance 0.06 Pain Relevance 0.03
The pH of the polymeric solution is also an important factor for NTX release.
Localization (release) of NTX
6) Confidence 0.15 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2948935 Disease Relevance 0 Pain Relevance 0.08
The data showed an increase in PF-127 content from 20% to 35%, resulting in a decrease in the rate of NTX release.
Localization (release) of NTX
7) Confidence 0.13 Published 2010 Journal Drug Des Devel Ther Section Abstract Doc Link PMC2948935 Disease Relevance 0.07 Pain Relevance 0.20
The results showed that the release of NTX from PF-127 hydrogel was affected by formulation variables of the gel.
Localization (release) of NTX
8) Confidence 0.13 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2948935 Disease Relevance 0 Pain Relevance 0.09
Sustained-release preparations of NTX have shown rather promising results.
Localization (release) of NTX
9) Confidence 0.13 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2948935 Disease Relevance 0.09 Pain Relevance 0.14
The effect of pH on NTX release was studied at vehicle pH values of 5.5, 7.4, and 8.5 using 25% PF-127 phosphate-buffered solutions (Figure 3).
Localization (release) of NTX
10) Confidence 0.13 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2948935 Disease Relevance 0 Pain Relevance 0
CD in molar ratios of 1:2 and 1:4 with no significant difference were able to prolong and control NTX release for more than 144 hours.
Localization (release) of NTX in molar
11) Confidence 0.13 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2948935 Disease Relevance 0 Pain Relevance 0
As shown in Figure 2, the highest concentration of PF-127 could sustain NTX release at about 55% in 10 hours and 70% in 48 hours, which is away from our desirable sustained profile release.
Localization (release) of NTX
12) Confidence 0.13 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2948935 Disease Relevance 0 Pain Relevance 0
However, because of its extensive first-pass metabolism, small treatment effect, plasma level fluctuations, adverse events, and poor patient adherence to the daily dosing schedule, clinical acceptance of this dosage form has been limited.15–17 Injectable sustained-release preparations of NTX can overcome these problems and improve the treatment outcome.18–20
Localization (release) of NTX in plasma
13) Confidence 0.13 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2948935 Disease Relevance 0.14 Pain Relevance 0.18
The results showed that pH 5.5 and 8.5 produced faster release of NTX among the studied formulations.
Localization (release) of NTX
14) Confidence 0.13 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2948935 Disease Relevance 0 Pain Relevance 0
Preparation of NTX PF-127 hydrogel formulation
Localization (Preparation) of NTX
15) Confidence 0.12 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2948935 Disease Relevance 0 Pain Relevance 0
In this study, diffusion cells were used to evaluate NTX release from the poloxamer hydrogels.21 The diffusion cells are comprised of two compartments separated by a cellulose acetate membrane (cutoff 12,000 Da), which does not constitute a barrier against NTX diffusion.
Localization (release) of NTX
16) Confidence 0.12 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2948935 Disease Relevance 0 Pain Relevance 0
Effect of formulation factors on in vitro release of NTX from PF-127 gel
Localization (release) of NTX
17) Confidence 0.12 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2948935 Disease Relevance 0 Pain Relevance 0
The in vitro release of NTX from these gel formulations was studied.


Localization (release) of NTX
18) Confidence 0.12 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2948935 Disease Relevance 0 Pain Relevance 0
The visual analogue scale (VAS) pain score, Roland Morris Disability Questionnaire (RDQ), Short Form-36 (SF-36) questionnaire, BMD and N-terminal telopeptide of type I collagen (NTx; a marker for bone resorption) were examined before and after treatment.
Spec (examined) Localization (telopeptide) of NTx associated with visual analogue scale, pain score and hypercalcemia
19) Confidence 0.11 Published 2010 Journal J Clin Neurosci Section Abstract Doc Link 20044258 Disease Relevance 0.87 Pain Relevance 0.65
The main objective of this study was to investigate thermosensitive Pluronic® F-127 (PF-127) hydrogel for the modified release of a potent alcohol and opioid antagonist, naltrexone (NTX) hydrochloride, in a subcutaneous injectable dosage form.


Localization (release) of NTX associated with antagonist, opioid and alcohol
20) Confidence 0.11 Published 2010 Journal Drug Des Devel Ther Section Abstract Doc Link PMC2948935 Disease Relevance 0.09 Pain Relevance 0.25

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox